SCHEMBL2008441

SCHEMBL2008441

CC1(C)Oc2cc3c(cc2C(NCCc2ccccc2)C1O)OCS(=O)(=O)N3

nearest known ligand 0.42

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 5/20 0.42
KCNA5 P22460 7/20 0.42
IDO1 P14902 3/20 0.36
KCNE1 P15382 3/20 0.34
KCNQ1 P51787 3/20 0.34
TP53 P04637 1/20 0.33
TAAR1 Q96RJ0 1/20 0.33
LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2869859 1.00 ABCB1 (0.42) ABCB1KCNA5IDO1KCNE1KCNQ1
SCHEMBL2009194 0.83 TP53 (0.47) ABCB1KCNA5TP53TAAR1LMNA
SCHEMBL2869709 0.83 TP53 (0.47) ABCB1KCNA5TP53TAAR1LMNA
SCHEMBL12580681 0.82 ABCB1 (0.46) ABCB1KCNA5IDO1TAAR1
SCHEMBL2006612 0.82 ABCB1 (0.46) ABCB1KCNA5IDO1TAAR1
SCHEMBL2013291 0.79 TP53 (0.47) ABCB1KCNA5TP53TAAR1LMNA
SCHEMBL2010054 0.79 TP53 (0.47) ABCB1KCNA5TP53TAAR1LMNA
SCHEMBL3603668 0.79 ABCB1 (0.52) ABCB1KCNA5IDO1
Fumaric Acid SCHEMBL2878032 0.79 ABCB1 (0.42) ABCB1KCNA5TAAR1
Maleic Acid SCHEMBL2889054 0.79 ABCB1 (0.42) ABCB1KCNA5TAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7964623-B2 Tricyclic benzopyrane compound NISSAN CHEMICAL INDUSTRIES LTD. (JP) 2011-06-21 US disclosed
US-20100069374-A1 Tricyclic benzopyrane compound NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2010-03-18 US disclosed
US-7652008-B2 2,2,7,9-tetramethyl-4-[(2-phenylethyl)amino]-3,4-dihydro-2H-pyrano[2,3-g]quinolin-3-ol; 3-hydroxy-2,2,9-trimethyl-4-[(2-phenylethyl)amino]-3,4-dihydro-2H-pyrano[2,3-g]quinolin-7-carbonitrile; have the prolongation effect on refractory period NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2010-01-26 US disclosed
US-20080004262-A1 Tricyclic Benzopyrane Compound as Anti-Arrhythmic Agents NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2008-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069374-A1 Tricyclic benzopyrane compound CBR1, CBR3, CYP2C9 ABCB1 647/4885KCNA5 101/4885IDO1 2850/4885
US-20080004262-A1 Tricyclic Benzopyrane Compound as Anti-Arrhythmic Agents CBR1, CBR3, SCN8A ABCB1 580/4885KCNA5 67/4885IDO1 3364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.